Hengfen Dai
Fujian Medical University(CN)First Affiliated Hospital of Fujian Medical University(CN)
Publications by Year
Research Areas
Atrial Fibrillation Management and Outcomes, Venous Thromboembolism Diagnosis and Management, Antiplatelet Therapy and Cardiovascular Diseases, Cardiac Arrhythmias and Treatments, Diabetes Treatment and Management
Most-Cited Works
- → Blockade of BDNF signalling attenuates chronic visceral hypersensitivity in an IBS‐like rat model(2020)44 cited
- → Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known(2023)41 cited
- → Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials(2021)36 cited
- → hsa-miR-4443 inhibits myocardial fibroblast proliferation by targeting THBS1 to regulate TGF-β1/α-SMA/collagen signaling in atrial fibrillation(2021)30 cited
- → Zeta Inhibitory Peptide as a Novel Therapy to Control Chronic Visceral Hypersensitivity in a Rat Model(2016)18 cited
- → MiRNA-1202 promotes the TGF-β1-induced proliferation, differentiation and collagen production of cardiac fibroblasts by targeting nNOS(2021)13 cited
- → Association between Body Mass Index and Clinical Outcomes in Patients with Non-valvular Atrial Fibrillation Receiving Direct Oral Anticoagulants: A New Piece of Evidence on the Obesity Paradox from China(2022)12 cited
- → Off-label dose direct oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation: A new evidence of Asian dose(2022)8 cited
- → Technology-Based Interventions in Oral Anticoagulation Management: Meta-Analysis of Randomized Controlled Trials(2020)8 cited
- The efficacy and safety of Sacubitril/Valsartan in the treatment of chronic heart failure: a meta-analysis.(2021)